Brief: Heat Biologics Says First Patient Treated In Co's First-In-Human Phase 1 Clinical Trial Evaluating PTX-35
22/06/2020 13:46
June 22 (Reuters) - Heat Biologics Inc HTBX.O :
* HEAT BIOLOGICS - FIRST PATIENT HAS BEEN TREATED IN CO'S
FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL EVALUATING PTX-35
* HEAT BIOLOGICS - FIRST-IN-HUMAN STUDY OF PTX-35 IS
EXPECTED TO
ENROLL UP TO 30 PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY
TO STANDARD OF CARE
Source text: (https://bit.ly/2CmsctJ)
Further company coverage: HTBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scorpius Holdings
See all newsBrief: Scorpius Holdings Inc Files For Non Timely 10-K With U.S. SEC
Brief: Scorpius Holdings Files For Offering Up To 29.4 Million Shares Of Common Stock
Brief: Scorpius Holdings Announces Collaboration With Celltheon Corporation
Brief: Scorpius Holdings - Implementation Of Strategic Cost-Saving Measures Expected To Save Over $2 Mln Annually
Brief: Scorpius Holdings Announces Partnership With U.S. Biotech Company